1. HBW Insight
  2. >>Geography
  3. >>Europe

Why Did Germany Reject Sildenafil OTC Switch?

 
• By David Ridley

Sildenafil was rejected at Germany’s independent switch committee’s most recent meeting. HBW Insight examines some of the arguments for and against the switch put forward by the regulator, members of the committee and the applicant, as recorded in the recently published minutes.

Rejected
• Source: Shutterstock

Germany’s medicines regulator BfArM recently published the minutes of its most recent Expert Committee on Prescription meeting, at which the Rx-to-OTC switch of erectile dysfunction treatment sildenafil (50mg) was discussed.

The switch was rejected, this much we know from the “short notice” published in January immediately after the meeting. But...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By David Ridley

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Pharma Deutschland Seeks To Enter Urban Wastewater Legal Dispute

 
• By David Ridley

The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.

Haleon Invests In State-Of-The-Art Oral Care R&D Facility In The UK

 
• By David Ridley

Haleon described the opening of a new oral care R&D facility in the UK as a “major investment reflecting our commitment to advancing science and innovation.”

More from Geography

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By David Ridley

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Survey Finds Brits Not Paying Enough Attention To Gum Health

 
• By David Ridley

Gum health awareness among British consumers could be better, a recent Haleon survey finds.

UK FSA Issues New Guidelines For CBD And THC Max Levels

 
• By David Ridley

Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.